Suppliers and packagers for ARISTADA INITIO KIT

ARISTADA INITIO KIT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alkermes Inc	ARISTADA INITIO KIT	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	209830	NDA	Alkermes, Inc.	65757-500-03	1 SYRINGE in 1 CARTON (65757-500-03) / 2.4 mL in 1 SYRINGE	2018-06-29
Alkermes Inc	ARISTADA INITIO KIT	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	209830	NDA	Alkermes, Inc.	65757-500-04	1 SYRINGE in 1 CARTON (65757-500-04) / 2.4 mL in 1 SYRINGE	2018-06-29

Suppliers and packagers for ARISTADA INITIO KIT

Last updated: June 4, 2026

Aristada Initio Kit Suppliers: Who Makes the Components, Holds the Supply Chain, and Supplies the U.S. Market

Aripiprazole lauroxil (Aristada) in the Aristada Initio kit is supplied through a defined U.S. manufacturing and distribution pipeline tied to the product’s branded developer and its contract manufacturing network. The kit is typically fulfilled by the drug’s U.S. holder’s labeled supply chain, with component manufacturing and fill-finish performed by one or more contract manufacturers that support the commercial sterile injectables workflow.

What company supplies Aristada Initio kit in the U.S. market?

Aristada Initio kit is marketed as a branded initiation regimen for aripiprazole lauroxil. In the U.S., the product’s labeled “Applicant/Holder” and the branded product’s distribution channel determine the practical supplier of record for procurement, contracting, and pharmacy wholesaler ordering.

Supplier of record (brand holder)

• Lundbeck (brand sponsor/distributor for Aristada products in the U.S.)

How this maps to real-world procurement

• For hospital systems, wholesalers, and group purchasing organizations, “supplier” usually means the labeled distributor and its distribution center network, while underlying manufacturing is performed under contract.

Who manufactures Aristada Initio kit?

Aristada Initio is an injectable product requiring sterile manufacturing and aseptic processing capabilities. Manufacturing responsibilities typically split into:

1. Drug substance manufacture (API and/or intermediate steps for aripiprazole lauroxil)
2. Drug product manufacturing (sterile fill-finish for the kit components)
3. Kitting and packaging (combining kit components into the marketed carton configuration)
4. Release and distribution (QA release, serialization where applicable)

Typical supplier pattern for Aristada-type long-acting injectable (LAI) kits

• Drug product and kitting: performed by contract sterile manufacturing sites aligned with the brand’s commercial supply plan.
• Labeling/distribution: performed by the brand holder’s U.S. distribution entities.

Which contract manufacturers support Aristada Initio kit supply chain?

Aristada Initio is a sterile injectable kit, so the manufacturing and fill-finish are performed by qualified sterile facilities used by the brand holder’s supply chain. The contract manufacturer identities are site-specific and can change over lifecycle due to:

• FDA manufacturing change control
• capacity rebalancing
• risk-based audits and remediation
• batch supply substitution under approved comparability protocols

Result for procurement

• For vendor selection, due diligence usually centers on:
  • sterile fill-finish capabilities for LAIs
  • controlled substance handling procedures where relevant (not always applicable for this specific product)
  • stable supply history and batch release performance

What components are included in the Aristada Initio kit, and who supplies each?

Aristada Initio is designed for initiation of aripiprazole lauroxil therapy. The kit includes dosing components used to start exposure while the long-acting injectable builds therapeutic levels.

Kit composition and procurement mapping

• Component drug products: sourced from the brand’s sterile manufacturing stream
• Kitting materials: supplied through the packaging qualification network tied to the product’s labeled configuration
• Carton/label/serialization: produced by packaging subcontractors under change-controlled product labeling processes

How does the Aristada Initio kit distribution network work for hospitals and wholesalers?

A U.S. branded kit is distributed via:

• national/regional pharmaceutical distribution centers supporting major wholesalers
• direct-to-provider channels where contracted
• refrigerated or controlled handling only if the labeled storage conditions require it (storage conditions are product-label dependent)

For Aristada Initio, the kit’s order fulfillment is governed by:

• wholesaler lead times
• lot allocation during supply constraints
• distribution center availability

What FDA regulatory disclosures identify manufacturers for Aristada Initio?

FDA product and labeling disclosures can identify:

• Applicant/Holder
• drug product manufacturing sites on relevant regulatory listings
• sterile facility roles (fill-finish and release)
• changes to manufacturing sites and packaging configurations over time

Those disclosures are typically accessible through FDA product databases and labeling records tied to the approved application.

What supply chain constraints are typical for LAI starter kits like Aristada Initio?

Starter kits for LAIs face constraints different from short-course generics:

• sterile fill-finish capacity limits
• long batch lead times for complex suspensions
• packaging line availability for kits and serialized presentations
• cold-chain or special handling rules if applicable
• controlled release uniformity and in-process control requirements

Procurement risk usually comes from:

• sterile line downtime
• component raw material volatility
• regulatory-driven changes to manufacturing sites

How do suppliers change over time: what to track for Aristada Initio?

For LAI kits, supplier changes happen via FDA-approved manufacturing supplements. The key tracking artifacts for ongoing supplier validation are:

• updates to manufacturing site listings
• changes to packaging configuration vendors (carton, labeling, serialization)
• changes in the lot release facility or QA release location
• any public supply disruptions affecting wholesalers

Key Takeaways

• In U.S. procurement terms, Lundbeck is the practical supplier-of-record for Aristada Initio kit ordering and distribution.
• Manufacturing and kitting for sterile LAI kits are typically executed by qualified contract sterile manufacturing and packaging partners integrated into the brand’s controlled supply chain.
• Supplier identification at the “who makes it” level is achieved through FDA disclosures and labeling-linked manufacturing site listings, which evolve with manufacturing supplements and capacity rebalancing.

FAQs

1. Is Lundbeck the manufacturer or the distributor for Aristada Initio kit?
   Lundbeck is the branded U.S. sponsor/distributor for procurement purposes; manufacturing is typically performed by qualified sterile contract facilities under the product’s regulatory framework.

2. What is the supplier-of-record for hospital purchasing of Aristada Initio?
   The supplier-of-record is the branded distribution channel aligned to the labeled holder for Aristada Initio, fulfilled through standard pharmaceutical wholesaler logistics.

3. Do kit components come from the same manufacturing site?
   LAI kits are usually manufactured from components that share the same sterile and packaging qualification framework, but component sourcing can be site-dependent within the brand’s approved manufacturing network.

4. How can a change in contract manufacturers affect availability of Aristada Initio?
   It can shift batch lead times, lot release timing, and kitting capacity, potentially affecting wholesaler allocation during transitions.

5. Where are manufacturing sites listed for Aristada products?
   Manufacturing sites are typically tied to FDA product and labeling records for the approved application and can be tracked through FDA listing updates.

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Drug approvals and product labeling for aripiprazole lauroxil (Aristada) and Aristada Initio. FDA.
2. U.S. Food and Drug Administration. (n.d.). Orange Book and related product information for Aristada/Aripiprazole lauroxil. FDA.
3. U.S. FDA. (n.d.). SPL and prescribing information records for Aristada Initio kit. FDA.